JP2022519696A5 - - Google Patents

Info

Publication number
JP2022519696A5
JP2022519696A5 JP2021546005A JP2021546005A JP2022519696A5 JP 2022519696 A5 JP2022519696 A5 JP 2022519696A5 JP 2021546005 A JP2021546005 A JP 2021546005A JP 2021546005 A JP2021546005 A JP 2021546005A JP 2022519696 A5 JP2022519696 A5 JP 2022519696A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021546005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519696A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/017314 external-priority patent/WO2020163778A1/en
Publication of JP2022519696A publication Critical patent/JP2022519696A/ja
Publication of JP2022519696A5 publication Critical patent/JP2022519696A5/ja
Pending legal-status Critical Current

Links

JP2021546005A 2019-02-07 2020-02-07 Tyk2偽キナーゼリガンド Pending JP2022519696A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802642P 2019-02-07 2019-02-07
US62/802,642 2019-02-07
PCT/US2020/017314 WO2020163778A1 (en) 2019-02-07 2020-02-07 Tyk2 pseudokinase ligands

Publications (2)

Publication Number Publication Date
JP2022519696A JP2022519696A (ja) 2022-03-24
JP2022519696A5 true JP2022519696A5 (cg-RX-API-DMAC7.html) 2023-02-15

Family

ID=71947508

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021546005A Pending JP2022519696A (ja) 2019-02-07 2020-02-07 Tyk2偽キナーゼリガンド

Country Status (12)

Country Link
US (1) US20220135567A1 (cg-RX-API-DMAC7.html)
EP (1) EP3920931A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022519696A (cg-RX-API-DMAC7.html)
KR (1) KR20210124409A (cg-RX-API-DMAC7.html)
CN (1) CN113677347A (cg-RX-API-DMAC7.html)
AU (1) AU2020218267A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021015616A2 (cg-RX-API-DMAC7.html)
CA (1) CA3129438A1 (cg-RX-API-DMAC7.html)
IL (1) IL285429A (cg-RX-API-DMAC7.html)
MX (1) MX2021009555A (cg-RX-API-DMAC7.html)
SG (1) SG11202108619SA (cg-RX-API-DMAC7.html)
WO (1) WO2020163778A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
SG11202110523XA (en) 2019-03-26 2021-10-28 Ventyx Biosciences Inc Tyk2 pseudokinase ligands
CN114929226B (zh) * 2019-11-08 2024-09-27 温缇克斯生物科学公司 Tyk2假激酶配体
IL301385A (en) * 2020-09-16 2023-05-01 Alumis Inc TYK2 inhibitors and their use
CN117043164A (zh) * 2021-01-19 2023-11-10 安锐生物医药科技(广州)有限公司 咪唑并哒嗪或吡唑并嘧啶化合物和组合物
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
CN121941683A (zh) * 2023-09-22 2026-04-28 杭州多域生物技术有限公司 含氮并环类化合物、其药物组合物及其应用
WO2025165746A1 (en) * 2024-01-30 2025-08-07 Ennovathera, Inc. Certain chemical entities, compositions, and methods
WO2025168035A1 (zh) * 2024-02-07 2025-08-14 合肥羿科医药有限公司 杂环类化合物、其药物组合物及其应用
CN118084920A (zh) * 2024-02-26 2024-05-28 镇江圣安医药有限公司 五元杂芳环并嘧啶-3-甲酰胺衍生物及其组合物和用途
WO2025214467A1 (zh) * 2024-04-12 2025-10-16 江苏恒瑞医药股份有限公司 氨基取代的杂芳环类化合物、其制备方法及其在医药上的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4564485B2 (ja) * 2003-02-28 2010-10-20 帝人ファーマ株式会社 ピラゾロ[1,5−a]ピリミジン誘導体
BRPI0914404A2 (pt) * 2008-10-31 2019-03-06 Genentech Inc "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente"
KR102782807B1 (ko) * 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
TW201720828A (zh) * 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
AU2018230737B2 (en) * 2017-03-08 2022-09-22 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
WO2018215390A1 (en) * 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
IL317854A (en) * 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
EP3849981B1 (en) * 2018-09-10 2023-02-01 Eli Lilly and Company Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
JP7619951B2 (ja) * 2018-10-15 2025-01-22 武田薬品工業株式会社 Tyk2阻害剤およびその使用
TWI800696B (zh) * 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
CN114929226B (zh) * 2019-11-08 2024-09-27 温缇克斯生物科学公司 Tyk2假激酶配体

Similar Documents

Publication Publication Date Title
JP2022529311A5 (cg-RX-API-DMAC7.html)
JP2022553841A5 (cg-RX-API-DMAC7.html)
JP2024520481A5 (cg-RX-API-DMAC7.html)
JP2022532877A5 (cg-RX-API-DMAC7.html)
RU2318816C2 (ru) 4-замещенные имидазол-2-тионы и имидазол-2-оны в качестве агонистов альфа2b- и альфа2c- адренергических рецепторов
JP2023518044A5 (cg-RX-API-DMAC7.html)
JP2024543512A5 (cg-RX-API-DMAC7.html)
JP2023553835A5 (cg-RX-API-DMAC7.html)
JP2020500178A5 (cg-RX-API-DMAC7.html)
JP2024529839A5 (cg-RX-API-DMAC7.html)
JP2022547617A5 (cg-RX-API-DMAC7.html)
JP2021522262A5 (cg-RX-API-DMAC7.html)
JP2024167182A5 (cg-RX-API-DMAC7.html)
JP2022550640A5 (cg-RX-API-DMAC7.html)
JP2012526728A5 (cg-RX-API-DMAC7.html)
JP2022538917A5 (cg-RX-API-DMAC7.html)
JP2017504576A5 (cg-RX-API-DMAC7.html)
IL292785B1 (en) TYK2 pseudokinase ligands
JP2018504437A5 (cg-RX-API-DMAC7.html)
JP2020529994A5 (cg-RX-API-DMAC7.html)
JP2024541910A5 (cg-RX-API-DMAC7.html)
JP2025513882A5 (cg-RX-API-DMAC7.html)
JP2011529468A5 (cg-RX-API-DMAC7.html)
JP2022552445A5 (cg-RX-API-DMAC7.html)
JP2022119852A5 (cg-RX-API-DMAC7.html)